plerenone（CAS:107724-20-9)

Eplerenone is a new generation of highly selective mineralocorticoid receptor antagonist with CAS No. 107724-20-9, serving as a high-end API for clinical cardiovascular treatment. It precisely blocks the binding of aldosterone to receptors and suppresses abnormal activation of the human renin-angiotensin-aldosterone system (RAAS), reducing sodium and water retention, vascular remodeling and myocardial fibrosis to deliver stable blood pressure reduction as well as cardiac and renal protective effects. Compared with the traditional spironolactone, eplerenone has extremely low affinity for sex hormone receptors, which completely avoids hormone-related side effects such as gynecomastia and menstrual disorders and greatly improves safety. Clinically, it is mainly applied to the treatment of primary hypertension, resistant hypertension and heart failure after myocardial infarction. It is a high-quality pharmaceutical raw material with integrated functions of hypotension, cardiac protection and target organ protection.

Eplerenone, CAS 107724-20-9, is a new-generation highly selective mineralocorticoid receptor antagonist and an innovative pharmaceutical API in the cardiovascular drug field. It effectively solves the side effect defects of traditional spironolactone and has become an essential raw material for the standardized treatment of hypertension and heart failure due to its high receptor selectivity, excellent safety and unique target organ protection performance. Appearing as white to pale yellow crystalline powder, Eplerenone has stable physical and chemical properties, good solubility and strict impurity control. Its pharmaceutical-grade purity meets international pharmacopoeia standards, making it suitable for large-scale production of oral tablets and other preparations, and widely used in global pharmaceutical manufacturing and new drug research.

In industrial production and market application, Eplerenone adopts mature synthetic technology with stable batch quality, high purity and low impurities, meeting the standards of high-end preparation production and export trade. With the comprehensive advantages of high efficiency, safety and multi-organ protection, Eplerenone has gradually replaced traditional spironolactone and become a first-choice API for clinical cardiovascular treatment. It has irreplaceable application value in clinical routine medication, adjuvant treatment of intractable cardiovascular diseases and high-end new drug research. With continuous growing global market demand, Eplerenone maintains broad development prospects in the pharmaceutical industry.

PREVIOUS：Torasemide（CAS:56211-40-6) NEXT：Amiloride hydrochloride(CAS:2016-88-8)